Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 443 across all filing types
Latest filing 2018-11-01 Board/Management Inform…
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
Nominated Adviser Status
Board/Management Information Classification · 1% confidence The document begins with 'RNS Number' and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content discusses a change in the company's Nominated Adviser (NOMAD) status, which is a regulatory requirement for AIM-listed companies, and mentions compliance with AIM Rule 1 and MAR regulations. This type of announcement, which is a formal regulatory update distributed via the RNS system, fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (like 10-K or IR), a management change (MANG), or a director's dealing (DIRS). Given the explicit RNS header and the nature of the announcement, RNS is the most appropriate code.
2018-11-01 English
Interim Results
Interim / Quarterly Report Classification · 1% confidence The document is an 'Interim Results Announcement' for ImmuPharma PLC for the six months ended 30 June 2018. It contains detailed financial highlights, a Chairman's statement, a financial review, and operational updates. It is a comprehensive report of financial performance for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2018
2018-09-26 English
Appointment of Joint Brokers
Board/Management Information Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states it is provided by RNS, the news service of the London Stock Exchange. The content announces the 'Appointment of Joint Brokers' (Stanford Capital Partners and SI Capital) and references a 'recently announced corporate update' as part of a proactive investor relations strategy. This type of announcement, which details changes in corporate advisory/brokerage relationships and is disseminated via the RNS system, fits best under the general 'Regulatory Filings' category, as there is no specific code for 'Broker Appointment'. It is not a financial report (10-K, IR, ER), a management change (MANG), or a director's dealing (DIRS). Therefore, RNS is the most appropriate classification.
2018-09-19 English
Corporate Update
Regulatory Filings Classification · 1% confidence The document is identified by the header 'RNS Number : 0607A' and the closing statement indicating the information is provided by 'RNS, the news service of the London Stock Exchange.' This strongly suggests it is a regulatory announcement. The content details several corporate updates: signing an agreement for a 'Managed Access Programme' for Lupuzor™, a clinical development collaboration for the Nucant programme involving an investment and licensing agreement, and the commencement of a divestment process for the Ureka subsidiary. These are operational and strategic updates, not a full financial report (like 10-K or IR) or a transcript. Since it is a general regulatory announcement detailing corporate actions and strategy updates, and it doesn't fit perfectly into specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate general regulatory filing category is RNS (Regulatory Filings), which serves as a fallback for miscellaneous regulatory announcements from exchanges like the LSE.
2018-09-07 English
Second Price Monitoring Extn
Regulatory Filings Classification · 1% confidence The document contains an 'RNS Number' and is dated July 10, 2018. The content discusses a 'Second Price Monitoring Extension' for a security, which is a specific operational announcement related to trading halts or extensions on an exchange. This type of general regulatory announcement that doesn't fit into specific financial reporting categories (like 10-K, ER, or DIV) is best classified under the general regulatory filing category, RNS (Regulatory News Service), which serves as the fallback for miscellaneous regulatory announcements.
2018-07-10 English
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1478 characters) and contains an 'RNS Number' and mentions the 'London Stock Exchange'. The content describes a 'Price Monitoring Extension' for an auction call period, which is a specific operational announcement related to trading mechanics rather than a comprehensive financial report or a standard corporate action like a dividend or management change. Since it is a regulatory announcement provided via RNS (the news service of the London Stock Exchange) and does not fit into the more specific categories (like ER, 10-K, DIV, etc.), it falls best under the general 'Regulatory Filings' fallback category, which corresponds to the RNS code.
2018-07-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.